Product Description: RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H2O2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice[1][2][3].
Applications: Metabolism-sugar/lipid metabolism
Formula: C20H26N6O2S2
References: [1]Mohammad S, et al. RG100204, A Novel Aquaporin-9 Inhibitor, Reduces Septic Cardiomyopathy and Multiple Organ Failure in Murine Sepsis. Front Immunol. 2022 Jun 14;13:900906./[2]Florio M, et al. Characterization of the Aquaporin-9 Inhibitor RG100204 In Vitro and in db/db Mice. Cells. 2022 Oct 4;11(19):3118./[3]Zhu QQ, et al. Downregulation of AQP9 Ameliorates NLRP3 Inflammasome-Dependent Inflammation and Pyroptosis in Crohn's Disease by Inhibiting the p38 MAPK Signaling Pathway. Mol Biotechnol. 2025 Feb 10.
CAS Number: 2140901-88-6
Molecular Weight: 446.59
Compound Purity: 99.50
Research Area: Infection; Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Aquaporin;NOD-like Receptor (NLR);p38 MAPK;Pyroptosis
Deutsch
English
